Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 6/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | HPGD | P15428 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.71 |
| ▸ | BLM | P54132 | 4/20 | 0.71 |
| ▸ | RECQL | P46063 | 3/20 | 0.71 |
| ▸ | POLB | P06746 | 3/20 | 0.71 |
| ▸ | APEX1 | P27695 | 3/20 | 0.71 |
| ▸ | GAA | P10253 | 3/20 | 0.71 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29357420 | 1.00 | EGFR (1.00) | EGFRKDM4EMEN1KMT2AERBB2 | |
| SCHEMBL6285299 | 1.00 | EGFR (1.00) | EGFRKDM4EMEN1KMT2AERBB2 | |
| SCHEMBL242896 | 1.00 | EGFR (1.00) | EGFRKDM4EMEN1KMT2AERBB2 | |
| SCHEMBL13060220 | 0.86 | EGFR (0.77) | EGFRKDM4EMEN1KMT2AERBB2 | |
| SCHEMBL5908882 | 0.85 | EGFR (1.00) | EGFRKDM4EMEN1KMT2AERBB2 | |
| SCHEMBL29483469 | 0.85 | EGFR (1.00) | EGFRKDM4EMEN1KMT2AERBB2 | |
| SCHEMBL29357482 | 0.85 | EGFR (1.00) | EGFRKDM4EMEN1KMT2AERBB2 | |
| SCHEMBL6286665 | 0.85 | EGFR (1.00) | EGFRKDM4EMEN1KMT2AERBB2 | |
| SCHEMBL17457139 | 0.85 | EGFR (1.00) | EGFRKDM4EMEN1KMT2AERBB2 | |
| Tyrphostin 47 SCHEMBL5802735 | 0.83 | EGFR (1.00) | EGFRKDM4EMEN1KMT2AERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1156775-B1 | REDUCTION OF HAIR GROWTH | GILLETTE CO (US) | 2006-05-17 | — | — | EP | claimed |
| EP-1156775-A1 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 2001-11-28 | — | — | EP | claimed |
| US-6121269-A | TOPICALLY APPLYING A PROTEIN-TYROSINE KINASE INHIBITOR TO SKIN TO REDUCE ANDROGEN-STIMULATED HAIR GROWTH WITHOUT SIDE EFFECTS | GILLETTE COMPANY, THE, A DELAWARE CORPORATION | 2000-09-19 | — | — | US | claimed |
| WO-2000050002-A1 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 2000-08-31 | — | — | WO | claimed |
| EP-0614661-A2 | Benzylidene- and cinnamylidine-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1994-09-14 | — | — | EP | claimed |
| EP-0322738-A2 | Benzylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1989-07-05 | — | — | EP | claimed |
| EP-4056677-A1 | COMPOSITIONS AND METHODS FOR EPITHELIAL STEM CELL EXPANSION AND CULTURE | The Brigham & Women's Hospital, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| EP-3702443-B1 | COMPOSITIONS AND METHODS FOR EPITHELIAL STEM CELL EXPANSION AND CULTURE | BRIGHAM & WOMENS HOSPITAL INC (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20210301254-A1 | Compositions And Methods For Epithelial Stem Cell Expansion And Culture | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-09-30 | — | — | US | disclosed |
| US-10954490-B2 | Compositions and methods for epithelial stem cell expansion and culture | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3702443-A1 | COMPOSITIONS AND METHODS FOR EPITHELIAL STEM CELL EXPANSION AND CULTURE | The Brigham and Women's Hospital, Inc. (US) | 2020-09-02 | — | — | EP | disclosed |
| EP-2970890-B1 | COMPOSITIONS AND METHODS FOR EPITHELIAL STEM CELL EXPANSION AND CULTURE | BRIGHAM & WOMENS HOSPITAL INC (US) | 2020-02-12 | — | — | EP | disclosed |
| US-10227355-B2 | Quinoline derivatives and preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2019-03-12 | — | — | US | disclosed |
| US-6121269-A | TOPICALLY APPLYING A PROTEIN-TYROSINE KINASE INHIBITOR TO SKIN TO REDUCE ANDROGEN-STIMULATED HAIR GROWTH WITHOUT SIDE EFFECTS | GILLETTE COMPANY, THE, A DELAWARE CORPORATION | 2000-09-19 | — | — | US | disclosed |
| WO-2000050002-A1 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 2000-08-31 | — | — | WO | disclosed |
| EP-0322738-B1 | Benzylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells | YISSUM RES DEV CO (IL) | 1995-04-12 | — | — | EP | disclosed |
| EP-0614661-A2 | Benzylidene- and cinnamylidine-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1994-09-14 | — | — | EP | disclosed |
| US-5217999-A | Antigrowth agents | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1993-06-08 | — | — | US | disclosed |
| WO-1991016892-A1 | STYRYL COMPOUNDS WHICH INHIBIT EGF RECEPTOR PROTEIN TYROSINE KINASE | RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1991-11-14 | — | — | WO | disclosed |
| EP-0322738-A2 | Benzylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1989-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227355-B2 | Quinoline derivatives and preparation thereof | ABL1, FLT3, MAP3K7 | EGFR 204/4885KDM4E 939/4885MEN1 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.